BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Egerton A. The potential of (1)H-MRS in CNS drug development. Psychopharmacology (Berl) 2021;238:1241-54. [PMID: 31486875 DOI: 10.1007/s00213-019-05344-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Bavato F, Esposito F, Dornbierer DA, Zölch N, Quednow BB, Staempfli P, Landolt H, Seifritz E, Bosch OG. Subacute changes in brain functional network connectivity after nocturnal sodium oxybate intake are associated with anterior cingulate GABA. Cerebral Cortex 2023. [DOI: 10.1093/cercor/bhad097] [Reference Citation Analysis]
2 Cao Z, Yu W, Zhang L, Yang J, Lou J, Xu M, Zhang Z. A study on the correlation of the asymmetric regulation between the periaqueductal gray and the bilateral trigeminal nucleus caudalis in migraine male rats. J Headache Pain 2023;24:27. [PMID: 36935501 DOI: 10.1186/s10194-023-01559-4] [Reference Citation Analysis]
3 Wieser M, Beckmann KM, Kutter APN, Mauri N, Richter H, Zölch N, Bektas RN. Ketamine administration in idiopathic epileptic and healthy control dogs: Can we detect differences in brain metabolite response with spectroscopy? Front Vet Sci 2022;9:1093267. [PMID: 36686158 DOI: 10.3389/fvets.2022.1093267] [Reference Citation Analysis]
4 English BA, Ereshefsky L. Experimental Medicine Approaches in Early-Phase CNS Drug Development. Adv Neurobiol 2023;30:417-55. [PMID: 36928860 DOI: 10.1007/978-3-031-21054-9_17] [Reference Citation Analysis]
5 Lacroix A, Proteau-lemieux M, Côté S, Near J, Hui SC, Edden RA, Lippé S, Çaku A, Corbin F, Lepage J. Multimodal assessment of the GABA system in patients with fragile-X syndrome and neurofibromatosis of type 1. Neurobiology of Disease 2022;174:105881. [DOI: 10.1016/j.nbd.2022.105881] [Reference Citation Analysis]
6 Jin B, Pang X, Zang Q, Ga M, Xu J, Luo Z, Zhang R, Shi J, He J, Abliz Z. Spatiotemporally resolved metabolomics and isotope tracing reveal CNS drug targets. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.11.011] [Reference Citation Analysis]
7 Vermeulen I, Isin EM, Barton P, Cillero-pastor B, Heeren RM. Multimodal molecular imaging in drug discovery and development. Drug Discovery Today 2022. [DOI: 10.1016/j.drudis.2022.04.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Roy AK, Ferrara E, Keesey R, Davis K. fMRI and Other Neuroimaging Methods. Comprehensive Clinical Psychology 2022. [DOI: 10.1016/b978-0-12-818697-8.00215-6] [Reference Citation Analysis]
9 Howes OD, Mehta MA. Challenges in CNS drug development and the role of imaging. Psychopharmacology (Berl) 2021;238:1229-30. [PMID: 33860824 DOI: 10.1007/s00213-021-05838-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
10 Syvänen S, Hammarlund-Udenaes M, Loryan I. In Vivo Studies of Drug BBB Transport: Translational Challenges and the Role of Brain Imaging. Handb Exp Pharmacol 2021. [PMID: 33387067 DOI: 10.1007/164_2020_425] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Merritt K, Catalan A, Cowley S, Demjaha A, Taylor M, McGuire P, Cooper R, Morrison P. Glyceryl trinitrate in first-episode psychosis unmedicated with antipsychotics: A randomised controlled pilot study. J Psychopharmacol 2020;34:839-47. [PMID: 32436761 DOI: 10.1177/0269881120922967] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]